Safety and patient experiences with the natalizumab biosimilar in multiple sclerosis treatment
While most patients perceived the biosimilar as equivalent to the originator, overall satisfaction was lower, and some reported more side effects. As these findings differ from blinded approval trials, a nocebo effect may influence patient perceptions in real-world settings when switching from originator to biosimilar natalizumab.
Authors
- Bob W. van Oosten (ORCID: https://orcid.org/0000-0003-4536-6201)
- Agnes I. Veldkamp
- Joep Killestein (ORCID: https://orcid.org/0000-0002-6347-5957)
- Eva M.M Strijbis
- Zoé L.E. van Kempen
- Liza M.Y. Gelissen
- B. A. de Jong
- Theo Rispens
Institutions
- Sanquin (NL)
- Amsterdam Neuroscience (NL)
- Amsterdam University Medical Centers (NL)
Publication Details
- Journal
- Multiple Sclerosis and Related Disorders
- Published
- 2026-03-16
- DOI
- https://doi.org/10.1016/j.msard.2026.107147
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amsterdam University Medical Centers